Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

被引：4

作者：

Evans, Rachel ^{[1
]}

Lee, Kelvin ^{[2
]}

Wallace, Paul K. ^{[1
]}

Reid, Mary ^{[1
]}

Muhitch, Jason ^{[1
]}

Dozier, Askia ^{[1
]}

Mesa, Circe ^{[3
]}

Luaces, Patricia L. ^{[3
]}

Santos-Morales, Orestes ^{[3
]}

Groman, Adrienne ^{[1
]}

Cedeno, Carlos ^{[1
]}

Cinquino, Aileen ^{[1
]}

Fisher, Daniel T. ^{[1
]}

Puzanov, Igor ^{[1
]}

Opyrchal, Mateusz ^{[2
]}

Fountzilas, Christos ^{[1
]}

Dai, Tong ^{[1
]}

Ernstoff, Marc ^{[4
]}

Attwood, Kristopher ^{[1
]}

Hutson, Alan ^{[1
]}

Johnson, Candace ^{[1
]}

Mazorra, Zaima ^{[3
]}

Saavedra, Danay ^{[3
]}

Leon, Kalet ^{[3
]}

Lage, Agustin ^{[3
]}

Crombet, Tania ^{[3
]}

Dy, Grace K. ^{[1
]}

机构：

[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY 14203 USA

[2] Indiana Univ, Dept Med, Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN USA

[3] Ctr Immunol Mol, Havana, La Habana, Cuba

[4] Natl Canc Inst NCI, Div Canc Treatment & Diag, Bethesda, MD USA

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

immunotherapy; lung cancer; non-small cell lung cancer; immune checkpoint inhibitor; vaccine; LONG-TERM SURVIVAL; LUNG-CANCER; CHECKMATE; 017; VACCINE; DOCETAXEL; OUTCOMES; THERAPY; BURDEN; PD-1;

D O I：

10.3389/fonc.2022.958043

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundCIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shown survival benefit as a switch maintenance treatment after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). The primary objective of this trial is to establish the safety and recommended phase II dose (RP2D) of CIMAvax-EGF in combination with nivolumab as second-line therapy for NSCLC. MethodsPatients with immune checkpoint inhibitor-naive metastatic NSCLC were enrolled using a "3+3" dose-escalation design. Toxicities were graded according to CTCAE V4.03. Thirteen patients (one unevaluable), the majority with PD-L1 0%, were enrolled into two dose levels of CIMAvax-EGF. FindingsThe combination was determined to be safe and tolerable. The recommended phase 2 dose of CIMAvax-EGF was 2.4 mg. Humoral response to CIMAvax-EGF was achieved earlier and in a greater number of patients with the combination compared to historical control. Four out of 12 evaluable patients had an objective response.

引用

页数：11

共 7 条

[1] Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC
Dy, G.
Dozier, A.
Reid, M.
Lee, K.
Miller, A.
Wallace, P.
Puzanov, I.
Opyrchal, M.
Ernstoff, M.
Johnson, C.
Mazorra, Z.
Saavedra, D.
Leon, K.
Lage, A.
Crombet, T.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S740 - S740
[2] A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Vadehra, Deepak
Janes, Cayla
Frascati, Rachel
Reid, Mary
Ramos, Tania C.
Mukherjee, Sarbajit
Monzon, Kalet L.
Alvarez, Patricia L.
Morales, Orestes S.
Pardillo, Circe M.
Fountzilas, Christos
CANCER RESEARCH, 2024, 84 (07)
[3] Ongoing Phase II Trial of Anti-PD1 Therapy in Combination with CIMAvax-EGF in Patients with Advanced NSCLC or Squamous Cell Head and Neck Cancer
Dy, G.
Crombet, T.
Leon, K.
Mazzora, Z.
Hernandez, D.
Lage, A.
Dozier, A.
Chen, H.
Hutson, A.
Plessinger, D.
Johnson, C.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S970 - S970
[4] Final results of the Phase I study of nivolumab in combination with CIMAvax, an epidermal growth factor(EGF)-depleting immunotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Focus on biomarker analyses
Dy, Grace K.
Lee, Kelvin
Groman, Adrienne
Cinquino, Aileen
Cedeno, Carlos
Minderman, Hans
Hutson, Alan
Wallace, Paul
Johnson, Candace
Mazorra, Zaima
Saavedra Hernandez, Danay
Leon, Kalet
Lage, Agustin
Crombet, Tania
CANCER RESEARCH, 2019, 79 (13)
[5] Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
Frascati, Rachel
Early, Amy P.
Reid, Mary E.
Lee, Kelvin
Muhitch, Jason
Mesa, Circe
Luaces, Patricia Lorenzo
Santos-Morales, Orestes
Dozier, Askia
Puzanov, Igor
Fountzilas, Christos
Gandhi, Shipra
Attwood, Kristopher
Hutson, Alan
Johnson, Candace S.
Herrera, Zaima
Saavedra, Danay
Leon, Kalet
Ramos, Tania Crombet
Dy, Grace K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] AN OPEN-LABEL, PHASE I/II DOSE-ESCALATION TRIAL INVESTIGATING ZALUTUMUMAB, A HUMAN MONOCLONAL EGF RECEPTOR (EGFR) ANTIBODY. IN COMBINATION WITH CHEMO-RADIATION AS FIRST LINE TREATMENT OF PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
Gregoire, V.
Maingon, P.
Nuyls, S.
Calais, G.
Gross, N.
Thelin, U.
Sorensen, P.
Nielsen, T.
Brun, E.
RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S309 - S310
[7] The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.
Long, Georgina V.
Lebbe, Celeste
Atkinson, Victoria
Mandala, Mario
Nathan, Paul D.
Arance, Ana
Richtig, Erika
Yamazaki, Naoya
Robert, Caroline
Schadendorf, Dirk
Tawbi, Hussein Abdul-Hassan
Ascierto, Paolo Antonio
Ribas, Antoni
Flaherty, Keith
Pakhle, Neha
Masood, Aisha
Gasal, Eduard
Dummer, Reinhard
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 →